Clinical trial

Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?

NCT02956811

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-02-14

PhasePHASE4

Study timeline

Study start (actual)2017-02-14Date precision: day

Registry last updated2019-07-09

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetesunresolved

Left Ventricular Hypertrophyunresolved

Interventions

DapagliflozinDRUG · verified · RxNorm: dapagliflozin

PlaceboDRUG

Sponsors & collaborators

University of Dundeelead sponsor

NHS Taysidecollaborator

AstraZenecacollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02956811 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.